This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schmalfeldt, B. Articles by Graeff, H. Search for Related Content PubMed PubMed Citation Articles by Schmalfeldt, B. Articles by Graeff, H.

Primary Tumor and Metastasis in Ovarian Cancer Differ in Their Content of Urokinase-type Plasminogen Activator, Its Receptor, and Inhibitors Types 1 and 2¹

Frauenklinik der Technischen Universität München, Klinikum rechts der Isar, Ismaninger Strasse 22, D-81675, Munich [B. S., W. K., U. R., L. P., M. S., F. J., H. G.], and Institut für Allgemeine Pathologie und Pathologische Anatomie, Technische Universität München [P. D., H. H.], Munich, Germany

The relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor (PAI) type 1 in predicting the survival probability of patients with advanced ovarian cancer after radical surgery and adjuvant chemotherapy by assessing the patients' primary tumors has recently been shown by us (W. Kuhn et al., Gynecol. Oncol., 55: 401–409, 1994). In the present study, we determined uPA, uPA receptor, PAI-1, and PAI-2 concentrations in primary tumors and tumor-infiltrated omentum and retroperitoneal lymph nodes of ovarian cancer patients. The group consisted of 39 patients with advanced ovarian carcinoma stages Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) IIIc or IV; for comparison 7 patients with early carcinoma stage FIGO I were also included. In metastases of the omentum from ovarian cancer stage FIGO IIIc or IV patients, we noted a 4-fold elevated uPA content, a 2-fold increase in PAI-1, and also a significant increase in uPA receptor and PAI-2 over primary tumors. In metastases of the lymph nodes the levels of the respective antigens were also increased when compared to primary tumors. These data may indicate that elevated levels of components of the fibrinolytic system at sites of metastases may contribute to the aggressive potential of cancer cells by favoring their reimplantation and/or the consolidation of a new tumor stroma.

¹ This work was supported by the Deutsche Forschungsgemeinschaft (Klinische Forschergruppe GR 280/4-1) and the BIOMED I program (BMH1CT931346).

² To whom requests for reprints should be addressed.

Received 6/15/95. Accepted 8/ 4/95.

This article has been cited by other articles:

				J.-H. Choi, K.-C. Choi, N. Auersperg, and P. C.K. Leung Gonadotropins Activate Proteolysis and Increase Invasion through Protein Kinase A and Phosphatidylinositol 3-Kinase Pathways in Human Epithelial Ovarian Cancer Cells. Cancer Res., April 1, 2006; 66(7): 3912 - 3920. [Abstract] [Full Text] [PDF]

				M. M. Heiss, E. H. Simon, B. C.M. Beyer, K. U. Gruetzner, A. Tarabichi, R. Babic, F. W. Schildberg, and H. Allgayer Minimal Residual Disease in Gastric Cancer: Evidence of an Independent Prognostic Relevance of Urokinase Receptor Expression by Disseminated Tumor Cells in the Bone Marrow J. Clin. Oncol., April 15, 2002; 20(8): 2005 - 2016. [Abstract] [Full Text] [PDF]

				M. D. Oberst, M. D. Johnson, R. B. Dickson, C.-Y. Lin, B. Singh, M. Stewart, A. Williams, A. al-Nafussi, J. F. Smyth, H. Gabra, et al. Expression of the Serine Protease Matriptase and Its Inhibitor HAI-1 in Epithelial Ovarian Cancer: Correlation with Clinical Outcome and Tumor Clinicopathological Parameters Clin. Cancer Res., April 1, 2002; 8(4): 1101 - 1107. [Abstract] [Full Text] [PDF]

				L. Rosano, M. Varmi, D. Salani, V. Di Castro, F. Spinella, P. Giorgio Natali, and A. Bagnato Endothelin-1 Induces Tumor Proteinase Activation and Invasiveness of Ovarian Carcinoma Cells Cancer Res., November 1, 2001; 61(22): 8340 - 8346. [Abstract] [Full Text] [PDF]

				B. Schmalfeldt, D. Prechtel, K. Harting, K. Spathe, S. Rutke, E. Konik, R. Fridman, U. Berger, M. Schmitt, W. Kuhn, et al. Increased Expression of Matrix Metalloproteinases (MMP)-2, MMP-9, and the Urokinase-Type Plasminogen Activator Is Associated with Progression from Benign to Advanced Ovarian Cancer Clin. Cancer Res., August 1, 2001; 7(8): 2396 - 2404. [Abstract] [Full Text] [PDF]

				T. B. Pustilnik, V. Estrella, J. R. Wiener, M. Mao, A. Eder, M.-A. V. Watt, R. C. Bast Jr., and G. B. Mills Lysophosphatidic Acid Induces Urokinase Secretion by Ovarian Cancer Cells Clin. Cancer Res., November 1, 1999; 5(11): 3704 - 3710. [Abstract] [Full Text] [PDF]

				G.-F. von Tempelhoff, K. Pollow, D. Schneider, and L. Heilmann State-of-the-Art Review : Chemotherapy and Thrombosis in Gynecologic Malignancy Clinical and Applied Thrombosis/Hemostasis, April 1, 1999; 5(2): 92 - 104. [PDF]